1024604-99-6

Basic information

• Product Name: 6-chloro-N-(2-hydroxy-2-(pyridin-3-yl)ethyl)pyridazine-3-carboxaMide
• Synonyms: 102035;6-chloro-N-(2-hydroxy-2-(pyridin-3-yl)ethyl)pyridazine-3-carboxaMide;3-Pyridazinecarboxamide, 6-chloro-N-[2-hydroxy-2-(3-pyridinyl)ethyl]-
• CAS NO: 1024604-99-6
• Molecular Formula: C12H11ClN4O2
• Molecular Weight: 278.69
• Mol File: 1024604-99-6.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-chloro-N-(2-hydroxy-2-(pyridin-3-yl)ethyl)pyridazine-3-carboxaMide(CAS DataBase Reference)
• NIST Chemistry Reference: 6-chloro-N-(2-hydroxy-2-(pyridin-3-yl)ethyl)pyridazine-3-carboxaMide(1024604-99-6)
• EPA Substance Registry System: 6-chloro-N-(2-hydroxy-2-(pyridin-3-yl)ethyl)pyridazine-3-carboxaMide(1024604-99-6)

Safety Data

• Hazardous Substances Data: 1024604-99-6(Hazardous Substances Data)

Usage

Chemical compound

6-chloropyridazine-3-carboxylic acid (2-hydroxy-2-pyridine-3-ylethyl)amide
Potential pharmaceutical applications
Derivative of pyridazine
Contains a carboxylic acid and an amide functional group
Contains chloro and hydroxyl groups, potentially useful building blocks for the synthesis of other complex organic molecules
May have biological activity and could function as a pharmaceutical intermediate
Interest to researchers in the pharmaceutical and chemical industries for the development of new drugs or compounds

Upstream product

• 37972-69-3 6-oxo-1,6-dihydropyridazine-3-carboxylic acid 
• 101012-01-5 2-amino-1-(pyridin-3-yl)ethanol dihydrochloride 

Downstream Products

• 1107014-69-6 6-[4-(2-methylbenzoyl)piperidin-1-yl]pyridazine-3-carboxylic acid (2-hydroxy-2-pyridin-3-ylethyl)amide 

Relevant articles and documents

Novel benzoylpiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 6-[4-(2-methylbenzoyl)piperidin-1-yl]pyridazine-3-carboxylic acid (2-hydroxy-2-pyridin-3-ylethyl)amide and its plasma triglyceride-lowering effects in Zucker fatty rats

Starting from a known piperazine-based SCD-1 inhibitor, we obtained more potent benzoylpiperidine analogs. Optimization of the structure of the benzoylpiperidine-based SCD-1 inhibitors resulted in the identification of 6-[4-(2-methylbenzoyl)piperidin-1-yl]pyridazine-3-carboxylic acid (2-hydroxy-2-pyridin-3-yl-ethyl)amide (24) which showed strong inhibitory activity against both human and murine SCD-1. In addition, this compound exhibited good oral bioavailability and demonstrated plasma triglyceride lowering effects in Zucker fatty rats in a dose-dependent manner after a 7-day oral administration (qd).